background:
The overexpression, accumulation, and cell-to-cell transmission of α-synuclein leads
to the deterioration of Parkinson’s disease (PD). Previous studies suggest that Baicalein (BAI) can bind to
α-synuclein and inhibit α-synuclein aggregation and secretion. However, it is still unclear whether BAI can
intervene with the pathogenic molecules in α-synuclein-mediated PD pathways besides targeting α-synuclein
per se.
method:
This study aimed to systematically investigate BAI’s potential targets in PD-related A53T mutant
α-synuclein-mediated pathways by integrating data mining, network pharmacological analysis, and molecular
docking simulation techniques.
result:
The results suggest that BAI may target genes that are dysregulated in synaptic transmission, vesicle
trafficking, gene transcription, protein binding, extracellular matrix formation, and kinase activity in
α-synuclein-mediated pathways. NFKB1, STAT3, and CDKN1A are BAI’s potential hub targets in these pathways.
conclusion:
Our study provides clues for future anti-PD drug development.